YAP (Yes-associated protein) regulates cell growth, tissue homeostasis, and organ size as a transcription co-activator in the Hippo tumor suppressor pathway. The kinase Lats inhibits YAP by phosphorylating it, causing it to localize to the cytoplasm and be degraded by proteasomes. By attaching to transcription factors from the TEAD family, YAP stimulates the expression of genes.
YAP has a complicated role in human cancer that may vary depending on the cell type. For instance, by inducing apoptosis in response to DNA damage, YAP may act as a tumor suppressor in some cell types, such as hematological cancers.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V69181 | (R)-VT104 | 2417718-26-2 | (R)-VT104 is the R-enantiomer of VT104. |
|
V79706 | AF-2112 | AF-2112 is a Flufenamic acid-derived TEAD inhibitor that strongly reduces the expression of CTGF, Cyr61, Axl, and NF2. | |
|
V69180 | DC-TEADin02 | 2380228-45-3 | DC-TEADin02 is a potent inhibitor of TEAD autopalmitoylation. |
|
V12043 | GA-017 | 2351906-74-4 | GA-017 is a potent and specific LATS1 and LATS2 (large tumor suppressor kinase 1/2) inhibitor (antagonist) with IC50s of 4.10 and 3.92 nM, respectively. |
|
V69176 | GNE-7883 | 2648450-42-2 | GNE-7883 is a generic TEAD inhibitor (antagonist) with anti-cell proliferation/growth activity. |
|
V69175 | IK-930 | 2563892-44-2 | IK-930 (compound I-32) is a potent orally bioactive TEAD inhibitor (antagonist) with EC50 <0.1 µM. |
|
V79966 | LM-41 | LM-41 is a Flufenamic acid-derived TEAD inhibitor that strongly reduces the expression of CTGF, Cyr61, Axl, and NF2. | |
|
V79664 | mCMY020 | mCMY020 is a TEAD covalent inhibitor. | |
|
V78452 | MY-1076 | MY-1076 is an inhibitor (blocker/antagonist) of YAP. | |
|
V2270 | MYF-01-37 | 2416417-65-5 | MYF-01-37 is a novel, potent and covalent TEAD inhibitor with anticancer activity. |
|
V3198 | Super-TDU | 1599441-71-0 | Super-TDU is a rationally designed peptide-based inhibitor targeting the YAP-TEADs interaction by mimicking the VGLL with anticancer activity. |
|
V81480 | Super-TDU (1-31) | Super-TDU (1-31) is the peptide fragment of Super-TDU. | |
|
V76465 | Super-TDU (1-31) (TFA) | Super-TDU (1-31) TFA is the peptide fragment of Super-TDU. | |
|
V81481 | Super-TDU TFA | Super-TDU TFA is a specific YAP antagonist that targets the YAP-TEAD interaction. | |
|
V69179 | SWTX-143 | 2766575-48-6 | SWTX-143 is a novel covalent YAP/TAZ-TEAD inhibitor that binds to the palmitoylation pocket of all four TEAD isoforms. |
|
V69183 | TEAD-IN-6 | 2821763-12-4 | TEAD-IN-6 (Example 11-1) is a TEAD modulator that blocks the interaction between YAP1/TAZ and TEAD. |
|
V38733 | TED-347 | 2378626-29-8 | TED-347 (TED347) is a novel,covalent/irreversible,and allostericYAP-TEAD protein-protein interaction inhibitor with anticancer activity. |
|
V69174 | TRULI (Lats-IN-1) | 1424635-83-5 | TRULI (Lats-IN-1) is a potent, ATP-competitive inhibitor of Lats1 and Lats2 kinases. |
|
V69178 | TT-10 (TAZ-K) | 2230640-94-3 | TT-10 (TAZ-K) is an activator of YES-associated protein (YAP)-transcription enhancer domain (TEAD) activity. |
|
V76351 | VT02956 | VT02956 is a LATS inhibitor (IC50= 0.76 nM for LATS1 and 0.52 nM for LATS2). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
